ADCs: Shaping the Future Treatment Paradigms in Solid Tumors As ADCs continue to be incorporated in the treatment landscape across several solid tumors, data emerging from the next wave of ADCs are adding to the excitement. JANUARY 2021 Syed Meheboob Ahmed, PhD,...
Too Big to Ignore: What CI Needs to Do to Make the China Market Manageable Chinese pharmaceutical companies present both an opportunity and a threat to their international counterparts. In this blog, we explore what Western pharmaceutical businesses need to do as the...
The Key to Successfully Navigating Chinese Pharmaceutical Regulations The Chinese regulatory landscape is very different compared to that of the rest of the world. Can businesses bridge the gap between the East and West? DECEMBER 2020 Dr. Aviral Maheshwari Vice...
ASH 2020 Highlights – Multiple Myeloma (MM) Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they might affect the treatment paradigm in MM. DECEMBER 2020 Prescient Analytics Jyotsana Chaudhary, MSc,...
ASH 2020 Highlights – Acute Myeloid Leukemia (AML) Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they might affect the treatment paradigm in AML. DECEMBER 2020 Prescient Analytics Shweta Srivastava,...
ASH 2020 Highlights – Diffuse Large B Cell Lymphoma (DLBCL) Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they might affect the treatment paradigm in DLBCL. DECEMBER 2020 Prescient Analytics Jyotsana...
